Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021
August 04, 2021 08:30 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2021 16:10 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors
August 02, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants
July 01, 2021 06:00 ET
|
Oyster Point Pharma, Inc.
Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of...
Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray
June 29, 2021 16:42 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray...
Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
June 21, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
June 21, 2021 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
June 10, 2021 07:00 ET
|
Oyster Point Pharma, Inc.
Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technologyOyster Point Pharma plans to discuss the potential for...
Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
June 03, 2021 08:00 ET
|
Oyster Point Pharma, Inc.
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK)Preclinical study results from a 42-day...
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 06, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDAOLYMPIA Phase 2 Study on Track,...